NCT03466320: A trial that was reported late by Celyad Oncology SA
This trial has reported, although it was 238 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03466320 |
|---|---|
| Title | An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients. |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 18, 2018 |
| Completion date | Feb. 1, 2021 |
| Required reporting date | Feb. 1, 2022, midnight |
| Actual reporting date | Sept. 27, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 238 |